title: [The effect of intravenously given amiodarone on maintenance of ventricular signal averaged electrocardiogram in patients with ischemic heart disease].
abstract: Recording of ventricular signal-averaged ECG (VSAE) were carried out in 19 patients suffering from ischemic heart disease before and after intravenously administration of amiodarone using a commercially available machine HIPEC-200 HA device of Aerotel's. The high gain ECG was recorded during basic rhythm with orthogonal Frank leads X, Y, Z. These combined into a vector magnitude and the QRS duration (QRS), the duration of low amplitude signals < 40 microV (LPD) and the root mean square voltage of the signals in the last 40 and 50 ms of the filtered QRS (RMS 40,50) were calculated for VSAE. It was time-domain analysis of VSAE. In frequency domain analysis were calculated the following parameters in range from 40 Hz to 400 Hz in linear scale: area ratio 20-50 Hz/0-20 Hz, peak and magnitude ratio and in logarithmic scale: energy spectrum > -60 dB and decibel drop at 40 Hz. Subsequently amiodarone hydrochloride was given intravenously 5 mg/kg c.c. and again time-domain and frequency domain analysis were done. Data presented are mean +/- standard deviation. Statistical comparisons were performed with paired t-Student test. Significance refers to a p values < 0.05. Time-domain analysis of VSAE didn't show any significant differences after amiodarone injection. During frequency-domain analysis of VSAE statistically significant differences were displayed in Frank lead X and Y for energy spectrum > -60 dB. In Frank lead X decrease of this parameter after amiodarone (from 3322 +/- 1057 dB-Hz to 2628 +/- 733) and in lead Y increase (from 2793 +/- 500 dB-Hz to 3199 +/-938 dB-Hz) was noticed. Our observation have indicated that intravenously application of amiodarone hydrochloride didn't change parameters in time-domain analysis. Statistically significant differences were noticed only during frequency analysis VSAE in logarithmic scale -energy spectrum > -60 dB but only in two leads X and Y.
authors.affiliation: Kliniki Chorób Wewnetrznych Wojskowego Szpitala Klinicznego, Wrocławiu.
authors.forename: W
authors.initials: W
authors.lastname: Banasiak
authors.forename: M
authors.initials: M
authors.lastname: Pieróg
authors.forename: K
authors.initials: K
authors.lastname: Kokot
authors.forename: A
authors.initials: A
authors.lastname: Fuglewicz
authors.forename: R
authors.initials: R
authors.lastname: Zapałowicz
authors.forename: A
authors.initials: A
authors.lastname: Telichowski
authors.forename: W
authors.initials: W
authors.lastname: Lacheta
authors.forename: W
authors.initials: W
authors.lastname: Molenda
authors.forename: J
authors.initials: J
authors.lastname: Góral
authors.forename: L
authors.initials: L
authors.lastname: Fudalej
authors.forename: I
authors.initials: I
authors.lastname: Pajak
authors.forename: C
authors.initials: C
authors.lastname: Telichowski
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012815:Signal Processing, Computer-Assisted
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone